U.S., Feb. 4 -- ClinicalTrials.gov registry received information related to the study (NCT06806046) titled 'Anti-CEACAM5 ADC M9140 in Chinese Participants With Solid Tumors (PROCEADE-CRC-02)' on Jan. 13.
Brief Summary: The purpose of this study is to evaluate the safety and early clinical activity of M9140 in Chinese participants with locally advanced or metastatic colorectal cancer (CRC).
Study Start Date: Dec. 20, 2024
Study Type: INTERVENTIONAL
Condition:
Solid Tumors
Colorectal Cancer
Intervention:
DRUG: M9140
M9140 will be administered every 3 weeks until progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study. There will be 2 dose levels, if the low dose level is tolerated, the...